The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real world comparison of time-to-next-treatment (TTNT), time-to-castration-resistance (TTCR), and overall survival (OS) among patients with BRCA1/2 positive and homologous recombination repair (HRR) negative metastatic castration-sensitive prostate cancer (mCSPC).
 
Heather Cheng
Consulting or Advisory Role - Janssen Oncology
Research Funding - Clovis Oncology (Inst); Janssen (Inst); Phosplatin Therapeutics (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Sabree Burbage
Employment - Janssen Scientific Affairs
Stock and Other Ownership Interests - Johnson & Johnson
 
Carmine Rossi
Consulting or Advisory Role - Eisai (Inst); Janssen Scientific Affairs (Inst); Merck (Inst)
 
Ibrahim Khilfeh
Employment - Janssen Scientific Affairs
Stock and Other Ownership Interests - Johnson & Johnson
 
Lilian Diaz
Consulting or Advisory Role - Janssen Scientific Affairs (Inst)
 
Yuxi Wang
Consulting or Advisory Role - Janssen Scientific Affairs (Inst)
 
Dominic Pilon
Consulting or Advisory Role - Janssen Scientific Affairs (Inst)
 
Gordon Brown
Honoraria - Astellas Pharma; Bayer; Janssen Oncology; Merck; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen Oncology; Merck; Pfizer
Speakers' Bureau - Astellas Pharma; Bayer; Janssen Oncology; Merck; Pfizer
Research Funding - Bayer; Janssen Oncology
Travel, Accommodations, Expenses - Bayer; Janssen Oncology; Pfizer
 
Neal Shore
Employment - GenesisCare
Consulting or Advisory Role - Accord Research; Alessa Therapeutics; Amgen; Antev; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Aura Biosciences; Bayer; Bioprotect; Bristol-Myers Squibb/Sanofi; CG Oncology; Clarity Pharmaceuticals; Dendreon; Exact Imaging; Ferring; Fize Medical; Glytherix; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Minomic; Myriad Genetics; Novartis; Peerview; Pfizer; Photocure; PlatformQ Health; Promaxo; Propella Therapeutics; Protara Therapeutics; Sanofi; Siemens; Speciality Networks; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tolmar; Tutelix; Urogen pharma
Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; SeaGen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow
 
Benjamin Lowentritt
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bayer; Blue Earth Diagnostics; Dendreon; Janssen Oncology; Merck; Pfizer; Sumitomo Pharma Oncology; Tolmar
Speakers' Bureau - Astellas Pharma; AstraZeneca/MedImmune; Bayer; Blue Earth Diagnostics; Janssen Oncology; Lantheus Medical Imaging; Merck; Myovant Sciences; Pfizer
Research Funding - Blue Earth Diagnostics; Dendreon; Janssen Oncology; Myovant Sciences
 
Daniel Lin
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Lantheus Medical Imaging
Research Funding - GenomeDx (Inst); Magforce (Inst); MDxHealth (Inst)
 
Mehmet Bilen
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; SeaGen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genome & Company (Inst); Incyte (Inst); Merck (Inst); Nektar (Inst); NiKang Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)